The Phase 3 PROOF-HD Trial Demonstrates Meaningful Benefits of Pridopidine on Function, Cognition, and Motor Signs in Huntington Disease (HD) (PL5.002)
Evaluate the safety and efficacy of pridopidine (45mg bid) in participants with HD (total functional capacity, TFC≥7).
Authors
- Diderik Boot
- Sandra K. Kostyk (ORCID: https://orcid.org/0000-0002-3371-753X)
- Ralf Reilmann (ORCID: https://orcid.org/0000-0002-5904-9517)
- Kelly S. Chen (ORCID: https://orcid.org/0000-0003-1473-864X)
- Randal Hand
- Michael R. Hayden (ORCID: https://orcid.org/0000-0001-5159-1419)
- Michal Geva (ORCID: https://orcid.org/0000-0002-6949-0963)
- Anne Rosser (ORCID: https://orcid.org/0000-0002-4716-4753)
- Paul Goldberg
- Yael Chava Cohen (ORCID: https://orcid.org/0000-0002-9061-7287)
- Andrew Feigin
Institutions
- University of British Columbia (CA)
- Hinge Health (US)
- University of Wales Institute Cardiff (SG)
- George Huntington Institute (DE)
- The Ohio State University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000212224
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00